CTLA4 and neoplasm: 1. High saturation of CTLA-4 on PD-1+ tumor cells by MEDI5752.2. Inhibition of CTLA-4 on TILs while sparing peripheral T cell populations and reducing toxicity.3. MEDI5752 induces internalisation and subsequent degradation of PD-1 by tethering CTLA-4 to PD-1.